Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd

Next 500 2024
+ 4 More
+ 4 More
OVERVIEW
FINANCIALS

Featured In Fortune India Ranking

Next 500 India
#413(2024)#224(2023)#59(2022)#115(2021)#160(2020)
#413(2024)#224(2023)#59(2022)#115(2021)#160(2020)
Ranking Trend Fortune Next 500 India

Financial Data 2024

Revenue
1,255
(INR Cr)
Net Operating Income
1,289
(INR Cr)
Assets
2,002
(INR Cr)
Profit
-567
(INR Cr)
Net Worth
934
(INR Cr)

Financial Data

RevenueNet Operating IncomeProfitAssetsNet Worth
PARAMETERS2024202320222021202020192018
Revenue
(INR Cr)
1255
-14.0%
1459
-5.7%
1547
-6.1%
1648
17.4%
1403
-2.1%
1433
172.5%
526
-
Net Operating Income
(INR Cr)
1289
-10.73%
1444
13.83%
1268
-21.56%
1617
22.33%
1322
-4.68%
1387
166.17%
521
0.00%
Profit
(INR Cr)
-567
-
-22
-
-58
-
221
93.2%
115
92.6%
60
-
0
-
Assets
(INR Cr)
2002
-21.9%
2565
-2.3%
2625
15.2%
2279
20.7%
1888
19.2%
1585
11.2%
1425
-
Net Worth
(INR Cr)
934
-37.8%
1500
-1.6%
1525
-4.0%
1589
46.3%
1086
13.6%
956
25.1%
764
0.0%
Employee Cost
(INR Cr)
244
6.7%
229
-3.3%
236
3.0%
229
12.4%
204
9.9%
186
171.1%
69
-
Interest Cost
(INR Cr)
105907584788225
Cash & Bank Balance
(INR Cr)
9947199577647
Total Debt
(INR Cr)
101210131037621722538633

Key Financial Ratios

Profit As % Of RevenuesRONW %Interest Cost to EBITDA %ROCE %Debt to Equity Ratio
PARAMETERS2024202320222021202020192018
Profit As % Of Revenues ---13.4%8.2%4.2%0.1%
Profit As % Of Assets ---9.7%6.1%3.8%0.0%
Profit As % Of Networth ---13.9%10.6%6.2%0.1%
Interest Cost to EBITDA % -67.3%98.4%21.9%30.0%38.7%44.2%
Debt to Equity Ratio 1.080.680.680.390.660.560.83
RONW ---16.6%11.2%6.9%0.2%
ROCE 0.0%1.7%-0.7%14.7%11.1%9.5%1.8%